Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, toward a Phase 2 clinical trial after favorable Phase 1 safety results. The therapy is designed to target demyelination and protect or restore myelin integrity, a key factor in multiple sclerosis progression.
In Phase 1 clinical studies involving healthy volunteers, LUCID-MS demonstrated a favorable safety profile and was generally well tolerated, supporting the company's decision to move into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, the required step to initiate a planned Phase 2 clinical trial in people living with multiple sclerosis. The company believes the therapy may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation.
To strengthen operational support for the program, Quantum BioPharma is planning a partnership with Allucent and engaging with neurological specialists. The company's lead compound, Lucid-MS, is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.
For more information, visit the company’s newsroom at https://ibn.fm/QNTM. The full article discussing this advancement is available at https://ibn.fm/AUhNl.
